T-cells comprising two different chimeric antigen receptors and uses thereof

US12139522B2 · kind B2 · utility

Assignees

• THE MEDICAL RESEARCH INFRASTRUCTURE AND HEAL SERVICED FUND OF THE TEL AVIV MEDECAL CENTER · IL
• YEDA RESEARCH AND DEVELOPMENT CO. LTD. · IL

Inventors

• Zelig Eshhar · Rehovot, IL
• Tova Waks · Netanya, IL
• Anat GLOBERSON LEVIN · Rehovot, IL
• Naamit Deshet-Unger · Ramat Gan, IL
• Moran RAWET SLOBODKIN · Tel Aviv-Yafo, IL
• Dan Grisaru · Herzliya, IL
• Ben Katz · Averill Park, US
• Ido Laskov · Tel Aviv-Yafo, IL

Key dates

• Filing date: Dec 4, 2018
• Grant date: Nov 12, 2024
• Expiry date: Feb 12, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2510/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides T-cells modified to express at least two chimeric antigen receptors, wherein one of the CARs binds specifically to an antigen selected from CD138, HER2 and CD24 and another CAR binds specifically a different antigen selected from CD 138, HER2 and CD24. Further, the invention provides pharmaceutical compositions comprising these CAR T-cells and their use in treatment of cancer, in particular, ovarian cancer, DNA constructs encoding said CARs and methods for preparation of T-cells expressing said CARs.